NCT01283776

Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation

A Phase II Study to Investigate the Efficacy of Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: University of Cologne · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and to describe the influence of the modified immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution and chimerism.

Conditions

• Multiple Myeloma
• Non-Hodgkin-Lymphoma
• Hodgkin's Disease

Interventions

Type	Name	Description
DRUG	Cyclophosphamide	100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-12-01
• Completion: 2014-06-01
• First posted: 2011-01-26
• Last updated: 2014-06-10

Locations

1 site across 1 country: Germany